Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib vs platinum chemotherapy in RET fusion-positive metastatic NSCLC (China)
CTR20210134Phase 3Terminated
- Sponsor
- Blueprint Medicines
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pralsetinib in non-small cell lung cancer (NSCLC), sponsored by Blueprint Medicines. Started Jan 2021; status: terminated.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210134.